Beam Therapeutics to cut 20% of workforce as part of restructuring plan

Beam Therapeutics said on Thursday it plans to reduce its headcount by about 100 employees, or 20% of its current workforce, as part of a restructuring plan.

The company said it will focus on developing its experimental sickle cell disease treatment and its program for alpha-1 antitrypsin deficiency (AATD), a condition that raises risk for lung and other diseases.